Drug Trial Radar · NCT04800263
A Trial of SHR-1905 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Jul 27, 2021
Primary completion
Nov 12, 2022
Study completion Nov 12, 2022
Sponsor
- Lead sponsor
- Atridia Pty Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of subcutaneous administered SHR-1905 in healthy subjects.
Conditions
- Asthma
Interventions
SHR-1905Drug
SHR-1905 will be injected subcutaneously
PlaceboDrug
Placebo will be injected subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Start of Treatment to end of study (approximately 16 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Brisbane, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.